Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

LOS ALTOS, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today

Related Keywords

United States ,University Of The Pacific ,California ,San Francisco ,Stockton ,American ,Shalabh Gupta ,Sara Kenkare Mitra ,Therapeutic Sciences ,Unicycive Therapeutics Inc ,University Of California ,Association For The Advancement Of Science ,Genentech ,Nasdaq ,Company Or Unicycive ,Exchange Commission ,Company Board Of Directors ,Development Sciences In Genentech ,Head Of Research ,Sciences Recognition ,Association Of Women ,National Academy Of Medicine ,Life Sciences ,Chief Executive ,Unicycive Board ,Senior Vice President ,Development Sciences ,New Drug ,Pharmaceutical Chemistry ,Post Doctoral Fellow ,Clinical Pharmacology ,National Academy ,American Association ,Pharmaceutical Scientist Alice ,Pharmaceutical Sciences Recognition ,Extraordinary Women ,Fierce Pharma ,Fiercest Women ,Distinguished Alumnus ,Private Securities Litigation Reform Act ,Risk Factor ,Annual Report ,Unicycive Therapeutics ,Region ,